Camp4 Therapeutics Corp unveils new preclinical data on SYNGAP1 seizure model in Boston

Camp4 Therapeutics Corp unveils new preclinical data on SYNGAP1 seizure model in Boston
Camp4 preclinical SYNGAP1 results

Camp4 Therapeutics Corp announced it will present new preclinical data at the TIDESUSA conference in Boston.

The company plans to showcase results demonstrating its lead candidate's ability to improve seizure threshold and severity in a SYNGAP1 disease model. The announcement is aimed at the scientific and medical communities, highlighting key advancements in early-stage research with potential implications for neurological disorders. Further details are available in the company's official press release.

Camp4 Therapeutics has previously detailed a new regRNA catalog powered by Capture-seq technology for gene expression in a preprint release. The company also hosted a ski outing last month to support team bonding and recognize employee contributions, according to a company announcement. These developments follow the ongoing expansion of Camp4’s scientific and organizational initiatives.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.